ArticleBioinformation2026
Intralesional triamcinolone versus 5-fluorouracil for keloids and hypertrophic scars: A randomized comparative clinical study.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keloids and hypertrophic scars lack a consistently effective and safe intralesional treatment and direct randomized comparisons between triamcinolone acetonide and 5-fluorouracil remain limited. Therefore, it is of interest to randomize clinical trial compared both agents in 100 patients treated over 12 weeks, evaluating scar height reduction, symptom improvement and adverse effects. Both treatments achieved significant scar flattening, with triamcinolone showing marginally greater mean height reduction. However, triamcinolone was associated with substantially higher rates of skin atrophy and telangiectasia, while 5-fluorouracil demonstrated a superior safety profile. Thus, we show 5-fluorouracil as a suitable first-line option for keloids and hypertrophic scars, especially in cosmetically sensitive areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.